U.S. Markets open in 3 hrs 20 mins
  • S&P Futures

    3,859.50
    -63.25 (-1.61%)
     
  • Dow Futures

    30,971.00
    -469.00 (-1.49%)
     
  • Nasdaq Futures

    11,726.00
    -209.50 (-1.76%)
     
  • Russell 2000 Futures

    1,746.00
    -26.80 (-1.51%)
     
  • Crude Oil

    106.81
    -2.78 (-2.54%)
     
  • Gold

    1,827.60
    +11.70 (+0.64%)
     
  • Silver

    21.52
    -0.02 (-0.09%)
     
  • EUR/USD

    1.0509
    +0.0043 (+0.4098%)
     
  • 10-Yr Bond

    2.8860
    0.0000 (0.00%)
     
  • Vix

    32.87
    +6.77 (+25.94%)
     
  • GBP/USD

    1.2414
    +0.0072 (+0.5810%)
     
  • USD/JPY

    127.7970
    -0.5000 (-0.3897%)
     
  • BTC-USD

    29,023.13
    -962.37 (-3.21%)
     
  • CMC Crypto 200

    645.38
    -25.30 (-3.77%)
     
  • FTSE 100

    7,244.97
    -193.12 (-2.60%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Nevro Corp. NVRO recently received the FDA’s approval for expanded labeling for its Senza Spinal Cord Stimulation (“SCS”) System associated with the treatment of non-surgical refractory back pain (“NSRBP”). The approval, which is specific to Nevro's exclusive 10 kHz Therapy, categorizes the Senza System as the only SCS system with specific labeling to treat NSRBP patients.

The FDA’s approval is backed by 12-month results for the SENZA-NSRBP randomized controlled trial (“RCT”), which was recently presented at the North American Neuromodulation Society.

The participants of the SENZA-NSRBP study indicated significant improvements in pain relief and other parameters against Conventional Medical Management (“CMM”) at 12 months post-implant. Results also included corresponding improvements for patients who shifted from CMM to 10 kHz after six months.

The latest regulatory clearance is expected to significantly strengthen Nevro’s foothold in the global SCS therapy business.

Significance of the Clearance

Management believes that the latest FDA approval for expanded labeling will expand access to 10 kHz Therapy for patients who suffer from intractable back pain without having undergone prior surgery, and have limited treatment options if they are not a candidate for surgery.

Following the approval of the expanded labeling, Nevro is currently the only SCS company with specific, on-label indications for treating both NSRBP and painful diabetic neuropathy (“PDN”) patients.

Industry Prospects

Per a report by Market Data Forecast, the global SCS market was estimated to be $1,871.6 million in 2020 and is anticipated to reach $2,827.4 million by the end of 2025 at a CAGR of 8.6%. Factors like rising cases of chronic and neuropathic pain, and growing adoption of SCS therapy are likely to drive the market.

Given the market potential, the latest FDA approval is expected to significantly boost Nevro’s business worldwide.

Recent Developments

This month, Nevro announced that private health insurance company UnitedHealthcare will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of PDN for dates of service on or after Mar 1, 2022.

In November 2021, Nevro announced three important clinical data publications for treating PDN with 10 kHz Therapy, including 12-month data from the SENZA-PDN RCT published online in Diabetes Care. The company also announced real-world evidence and a comparative literature review of high versus low-frequency SCS evidence, both published in the Journal of Diabetes Science and Technology. Findings from all three studies highlight the significant benefits of HFX for PDN in clinical and real-world settings.

Price Performance

Shares of the company have lost 52.6% in the past year compared with the industry’s 7.8% fall. The S&P 500 has risen 19.2% in the same time frame.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Zacks Rank & Key Picks

Currently, Nevro carries a Zacks Rank #3 (Hold).

A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, Cerner Corporation CERN and Catalent, Inc. CTLT.

AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.51%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

AMN Healthcare has gained 36.4% against the industry’s 59.3% fall over the past year.

Cerner, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 12.8%. CERN’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 3.21%.

Cerner has gained 15.3% against the industry’s 55.1% fall over the past year.

Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.88%. It currently carries a Zacks Rank #2.

Catalent has lost 13.3% compared with the industry’s 30.5% fall over the past year.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cerner Corporation (CERN) : Free Stock Analysis Report

AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report

Nevro Corp. (NVRO) : Free Stock Analysis Report

Catalent, Inc. (CTLT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research